Ocular pharmacokinetics of naringenin eye drops following topical administration to rabbits

Journal of Ocular Pharmacology and Therapeutics

Volumn 31, Issue 1, 2015, Pages 51-56

  Lin, Junli ^a   Sun, Jingjing ^b   Wang, Yandong ^c   Ma, Yan ^a   Chen, Wenpei ^a   Zhang, Ziyang ^a   Gui, Gang ^a   Lin, Baoqin ^a  

^a GUANGZHOU UNIVERSITY OF CHINESE MEDICINE   (China)

^b UNIVERSITY OF THE PACIFIC   (United States)

^c SUN YAT SEN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

NARINGENIN; ANTINEOPLASTIC AGENT; EYE DROPS; FLAVANONE DERIVATIVE;

ANIMAL EXPERIMENT; AQUEOUS HUMOR; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; ELECTROSPRAY; EXPERIMENTAL RABBIT; FEMALE; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; QUALITY CONTROL; TANDEM MASS SPECTROMETRY; TIME TO MAXIMUM PLASMA CONCENTRATION; VITREOUS BODY; ANIMAL; ELECTROSPRAY MASS SPECTROMETRY; EYE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; METABOLISM; PROCEDURES; RABBIT; RANDOMIZATION; TISSUE DISTRIBUTION; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, TOPICAL; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CHROMATOGRAPHY, LIQUID; EYE; FEMALE; FLAVANONES; MALE; OPHTHALMIC SOLUTIONS; RABBITS; RANDOM ALLOCATION; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; TANDEM MASS SPECTROMETRY; TISSUE DISTRIBUTION;

EID: 84920759579     PISSN: 10807683     EISSN: 15577732     Source Type: Journal    
DOI: 10.1089/jop.2014.0047     Document Type: Article

References (26)

1. Lin, B.Q., Li, P.B., Wang, Y.G., et al. The expectorant activity of naringenin. Pulm. Pharmacol. Ther. 21:259-263, 2008.
2. Vafeiadou, K., Vauzour, D., Lee, H.Y., et al. The citrus flavanone naringenin inhibits inflammatory signalling in glial cells and protects against neuroinflammatory injury. Arch. Biochem. Biophys. 484:100-109, 2009.
3. Ors?olić, N., Gajski, G., Garaj-Vrhovac, V., et al. DNAprotective effects of quercetin or naringenin in alloxaninduced diabetic mice. Eur. J. Pharmacol. 656:110-118, 2011.
4. Ma, Y., Li, P., Chen, D., et al. LC/MS/MS quantitation assay for pharmacokinetics of naringenin and double peaks phenomenon in rats plasma. Int. J. Pharm. 307:292-299, 2006.
5. Shen, Y., Zhang, W.Y., and Chiou, G.C. Effect of naringenin on NaIO(3)-induced retinal pigment epithelium degeneration and laser-induced choroidal neovascularization in rats. Int. J. Ophthalmol. 3:5-8, 2010.
6. Park, Y.H., and Chiou, G.C. Structure-activity relationship (SAR) between some natural flavonoids and ocular blood flow in the rabbit. J. Ocul. Pharmacol. Ther. 20:35-42, 2004.
7. Park, Y.H., Xu, X.R., and Chiou, G.C. Structure requirements of flavonoids for increment of ocular blood in the rabbit and retinal function recovery in rat eyes. J. Ocul. Pharmacol. Ther. 20:189-200, 2004.
8. Xu, X.R., Park, Y.H., and Chiou, G.C. Effects of dihydrogenation of flavones and number of hydroxy groups in the molecules on ocular blood flow in rabbits and retinal function recovery in rats. J. Ocul. Pharmacol. Ther. 20: 311-320, 2004.
9. Lin, B.Q., and Chiou, G.C. Antioxidant activity of naringenin on various oxidants induced damages in ARPE-19 cells and HUVEC. Int. J. Ophthalmol. 2:113-117, 2008.
10. Lin, J.L., Wang, Y.D., Ma, Y., et al. Protective effect of naringenin eye drops on N-methyl-N-nitrosourea-induced photoreceptor cell death in rats. Int. J. Ophthalmol. 3:391-396, 2014.
11. Shah, V.P., Midha, K.K., Dighe, S., et al. Analytical methods validation: Bioavailability, bioequivalence, and pharmacokinetic studies. J. Pharm. Sci. 81:309-312, 1992.
12. Shah, V.P., Midha, K.K., Findlay, J.W., et al. Bioanalytical method validation-A revisit with a decade of progress. Pharm. Res. 17:1551-1557, 2000.
13. Food and Drug Administration, Guidance for Industry Bioanalytical method validation, 2001. http://www.fda.gov/downloads/Drugs/Guidances/ucm070107.pdf, accessed on May 15, 2014.
14. Wu, C., Qi, H., Chen, W., et al. Preparation and evaluation of a Carbopol/HPMC-based in situ gelling ophthalmic system for puerarin. Yakugaku. Zasshi. 127:183-191, 2007.
15. Kerec, M., Bogataj, M., Mugerle, B., Gas?perlin, M., and Mrhar, A. Mucoadhesion on pig vesical mucosa: Influence of polycarbophil/calcium interactions. Int. J. Pharm. 241: 135-143, 2002.
16. See, N.A., Russell, J., Connors, K.A., and Bass, P. Adsorption of inorganic and organic ions to polycarbophil as a means of sustained-release dosage formulation. Pharm. Res. 4:244-247, 1987.
17. Bowman, L.M., Si, E., Pang, J., Archibald, R., and Friedlaender, M. Development of a topical polymeric mucoadhesive ocular delivery system for azithromycin. J. Ocul. Pharmacol. Ther. 25:133-140, 2009.
18. Geroski, D.H., and Edelhauser, H.F. Transscleral drug delivery for posterior segment disease. Adv. Drug Deliv. Rev. 52:37-48, 2001.
19. Myles, M.E., Neumann, D.M., and Hill, J.M. Recent progress in ocular drug delivery for posterior segment disease: Emphasis on transscleral iontophoresis. Adv. Drug Deliv. Rev. 57:2063-2079, 2005.
20. Loftsson, T., Sigurdsson, H.H., Konrádsdóttir, F., et al. Topical drug delivery to the posterior segment of the eye: Anatomical and physiological considerations. Pharmazie. 63:171-179, 2008.
21. Barar, J., Javadzadeh, A.R., and Omidi, Y. Ocular novel drug delivery: Impacts of membranes and barriers. Expert. Opin. Drug Deliv. 5:567-581, 2008.
22. Gaudana, R., Jwala, J., Boddu, S.H., and Mitra, A.K. Recent perspectives in ocular drug delivery. Pharm. Res. 26:1197-1216, 2009.
23. Gaudana, R., Ananthula, H.K., Parenky, A., and Mitra, A.K. Ocular drug delivery. AAPS J. 12:348-360, 2010.
24. Ahmed, I., and Patton, T.F. Importance of the noncorneal absorption route in topical ophthalmic drug delivery. Invest. Ophthalmol. Vis. Sci. 26:584-587, 1985.
25. Majumdar, S., and Srirangam, R. Solubility, stability, physicochemical characteristics and in vitro ocular tissue permeability of hesperidin: A natural bioflavonoid. Pharm. Res. 26:1217-1225, 2009.
26. Kesavan, K., Kant, S., Singh, P.N., and Pandit, J.K. Effect of Hydroxypropyl-b-cyclodextrin on the ocular bioavailability of dexamethasone from a pH-induced mucoadhesive hydrogel. Curr. Eye Res. 36:918-929, 2011.